Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner
Rate ePoster

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

TME-responsive detachable PEG masking for immune-selective safety and restored antitumor efficacy

Jae Hyung Park – Professor, Chemical Engineering, Sungkyunkwan University; Seok Ho Song – Ph.D., Chemical Engineering, Sungkyunkwan University; Torsha Ghosh – Ph.D., Chemical Engineering, Sungkyunkwan University

    Poster Presenter(s)

  • Chaemin Lee, B.S.

    Combined M.S./Ph.D. Student
    Sungkyunkwan University, Republic of Korea

Introduction:

Monoclonal antibodies targeting immune checkpoint pathways can produce durable clinical responses, but overall response rates remain low (~10–30%). Efforts to improve efficacy via dose escalation or combination therapy often increase immune-related adverse events (irAEs) because antigens are shared between tumors and normal tissues. Managing these toxicities with corticosteroids or immunosuppressants can weaken antitumor immunity and diminish benefit. Therefore, site-specific activation strategies are needed to minimize systemic toxicity while preserving antitumor efficacy.

Learning Objectives:

  • Understand ICB mechanisms and the pathogenesis/types of immune-related adverse events.
  • Recognize the necessity of TME targeting strategy to mitigate systemic toxicity and enhance therapeutic efficacy.
  • Develop a versatile antibody-engineering platform that overcome the limitations of current therapies.